PortalPublikationenCondensed versus standard schedule of high-dose cytarabine c...

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

Standard

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. / Jaramillo, S; Benner, A; Krauter, J; Martin, Hans; Kindler, T; Bentz, Martin; Salih, H R; Held, G; Köhne, C-H; Götze, Katharina; Lübbert, M; Kündgen, A; Brossart, P; Wattad, M; Salwender, H; Hertenstein, B; Nachbaur, D; Wulf, G; Horst, H-A; Kirchen, H; Fiedler, W; Raghavachar, A; Russ, Graeme; Kremers, S; Koller, E; Runde, V; Heil, G; Weber, D; Göhring, G; Döhner, K; Ganser, A; Döhner, H; Schlenk, R F.

in: BLOOD CANCER J, Jahrgang 7, Nr. 5, 26.05.2017, S. e564.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Jaramillo, S, Benner, A, Krauter, J, Martin, H, Kindler, T, Bentz, M, Salih, HR, Held, G, Köhne, C-H, Götze, K, Lübbert, M, Kündgen, A, Brossart, P, Wattad, M, Salwender, H, Hertenstein, B, Nachbaur, D, Wulf, G, Horst, H-A, Kirchen, H, Fiedler, W, Raghavachar, A, Russ, G, Kremers, S, Koller, E, Runde, V, Heil, G, Weber, D, Göhring, G, Döhner, K, Ganser, A, Döhner, H & Schlenk, RF 2017, 'Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia', BLOOD CANCER J, Jg. 7, Nr. 5, S. e564. https://doi.org/10.1038/bcj.2017.45

APA

Jaramillo, S., Benner, A., Krauter, J., Martin, H., Kindler, T., Bentz, M., Salih, H. R., Held, G., Köhne, C-H., Götze, K., Lübbert, M., Kündgen, A., Brossart, P., Wattad, M., Salwender, H., Hertenstein, B., Nachbaur, D., Wulf, G., Horst, H-A., ... Schlenk, R. F. (2017). Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. BLOOD CANCER J, 7(5), e564. https://doi.org/10.1038/bcj.2017.45

Vancouver

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. BLOOD CANCER J. 2017 Mai 26;7(5):e564. https://doi.org/10.1038/bcj.2017.45

Bibtex

@article{4043c47ebfbc452e9b2b5dd914eeb154,
title = "Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia",
abstract = "The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.",
keywords = "Journal Article",
author = "S Jaramillo and A Benner and J Krauter and Hans Martin and T Kindler and Martin Bentz and Salih, {H R} and G Held and C-H K{\"o}hne and Katharina G{\"o}tze and M L{\"u}bbert and A K{\"u}ndgen and P Brossart and M Wattad and H Salwender and B Hertenstein and D Nachbaur and G Wulf and H-A Horst and H Kirchen and W Fiedler and A Raghavachar and Graeme Russ and S Kremers and E Koller and V Runde and G Heil and D Weber and G G{\"o}hring and K D{\"o}hner and A Ganser and H D{\"o}hner and Schlenk, {R F}",
year = "2017",
month = may,
day = "26",
doi = "10.1038/bcj.2017.45",
language = "English",
volume = "7",
pages = "e564",
journal = "BLOOD CANCER J",
issn = "2044-5385",
publisher = "NATURE PUBLISHING GROUP",
number = "5",

}

RIS

TY - JOUR

T1 - Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

AU - Jaramillo, S

AU - Benner, A

AU - Krauter, J

AU - Martin, Hans

AU - Kindler, T

AU - Bentz, Martin

AU - Salih, H R

AU - Held, G

AU - Köhne, C-H

AU - Götze, Katharina

AU - Lübbert, M

AU - Kündgen, A

AU - Brossart, P

AU - Wattad, M

AU - Salwender, H

AU - Hertenstein, B

AU - Nachbaur, D

AU - Wulf, G

AU - Horst, H-A

AU - Kirchen, H

AU - Fiedler, W

AU - Raghavachar, A

AU - Russ, Graeme

AU - Kremers, S

AU - Koller, E

AU - Runde, V

AU - Heil, G

AU - Weber, D

AU - Göhring, G

AU - Döhner, K

AU - Ganser, A

AU - Döhner, H

AU - Schlenk, R F

PY - 2017/5/26

Y1 - 2017/5/26

N2 - The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.

AB - The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.

KW - Journal Article

U2 - 10.1038/bcj.2017.45

DO - 10.1038/bcj.2017.45

M3 - SCORING: Journal article

C2 - 28548643

VL - 7

SP - e564

JO - BLOOD CANCER J

JF - BLOOD CANCER J

SN - 2044-5385

IS - 5

ER -